Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

DualityBio Sells Two ADC Assets to BioNTech for $170 Million Upfront, $1.5 Billion in Milestones

publication date: Apr 3, 2023

Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner for one of the two original COVID vaccines, in a deal worth $170 million upfront and up to $1.5 billion in milestone payments. The agreement includes Duality’s lead candidate, DB-1303, a topoisomerase-1 inhibitor-based ADC directed against HER2, currently in a Phase II clinical trial. BioNTech will also acquire Duality’s second topoisomerase-1 inhibitor-based ADC candidate, DB-1311. DualityBio will be eligible to receive single-digit to double-digit tiered royalties on sales for both assets. More details....

Stock Symbol: (NSDQ: BNTX)

Share this with colleagues: